271 related articles for article (PubMed ID: 20595207)
1. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Ge Y
J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
[TBL] [Abstract][Full Text] [Related]
2. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
Mushtaq S; Warner M; Williams G; Critchley I; Livermore DM
J Antimicrob Chemother; 2010 Jul; 65(7):1428-32. PubMed ID: 20478991
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Karlsson IM; Ge Y; Giske CG
Diagn Microbiol Infect Dis; 2011 May; 70(1):137-41. PubMed ID: 21513849
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Melchers MJ; van Mil AC; Mouton JW
Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
Livermore DM; Yuan M
J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.
Sader HS; Rhomberg PR; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2011 May; 55(5):2390-4. PubMed ID: 21321149
[TBL] [Abstract][Full Text] [Related]
9. Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.
Mushtaq S; Hope R; Warner M; Livermore DM
J Antimicrob Chemother; 2007 May; 59(5):1025-30. PubMed ID: 17353220
[TBL] [Abstract][Full Text] [Related]
10. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
Livermore DM; Mushtaq S; Meunier D; Hopkins KL; Hill R; Adkin R; Chaudhry A; Pike R; Staves P; Woodford N;
J Antimicrob Chemother; 2017 Aug; 72(8):2278-2289. PubMed ID: 28520867
[TBL] [Abstract][Full Text] [Related]
11. Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens.
Livermore DM; Mushtaq S; Warner M; Turner SJ; Woodford N
J Antimicrob Chemother; 2018 Jan; 73(1):126-133. PubMed ID: 29059308
[TBL] [Abstract][Full Text] [Related]
12. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Juan C; Zamorano L; Pérez JL; Ge Y; Oliver A; ;
Antimicrob Agents Chemother; 2010 Feb; 54(2):846-51. PubMed ID: 19933793
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Prakash SK; Arora V; Prashad R; Sharma VK
J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
[TBL] [Abstract][Full Text] [Related]
15. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
Livermore DM; Mushtaq S; Ge Y; Warner M
Int J Antimicrob Agents; 2009 Nov; 34(5):402-6. PubMed ID: 19428220
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Taneja N; Rao P; Arora J; Dogra A
Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
18. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Peterson LR
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
[TBL] [Abstract][Full Text] [Related]
20. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
